Гематологии и онкологии детской оссийский р урнал ж 54 Оригинальные исследования Тромбоцитопатии И. А. Дёмина

partner 

β

3. Blood 1999;94:2039–47.

11. Shattil S. J. Signaling through platelet 

integrin alpha IIb beta 3: inside-out, outside-

in, and sideway. Thromb Haemost 

1999;82:318–25.

12. Еmambokus N. R., Frampton J. The 

glycoprotein IIb molecule is expressed on 

early murine hematopoietic progenitors and 

regulates their numbers in sites of 

hematopoiesis. Immunity 2003;19:33–45.

13. Arnaout M. A., Mahalingam B., 

Xiong J. P. Integrin structure, allostery, and 

bidirectional signalling. Annu Rev Cell Biol 

2005;21:381–41.

14. Calvete J. J. On the structure and function 

of platelet integrin alpha IIb beta 3, the 

fibrinogen receptor. Proc Soc Exp Biol Med 

1995;208:346–60.

15. Mitchell W. B., Li J. H., French D. L. et al. 

AlphaIIbbeta3 biogenesis is controlled by 

engagement of alphaIIb in the calnexin cycle 

via the N15-linked glycan. Blood 

2006;107:2713–9.

16. Wilcox D. A., Wautier J. L., Pidard D. 

et al. A single amino acid substitution 

flanking the fourth calcium binding domain 

of alphaIIb prevents maturation of the 

alphaIIbbeta3 integrin complex. J Biol Chem 

1994;269:4450–7.

17. Nelson E. J., Li J., Mitchell W. B. et al. 

Three novel betapropeller mutations causing 

Glanzmann thrombasthenia result in 

production of normally stable pro-alphaIIb 

but variably impaired progression of pro-

alphaIIbbeta3 from endoplasmic reticulum 

to Golgi. J Thromb Haemost  

2005;3:2773–83.

18. Gonzalez-Manchon C., 

 Arias-Salgado E. G., Butta N. et al. A novel 

homozygous splice junction mutation in 

GPIIb associated with alternative splicing, 

nonsense-mediated decay of GPIIbmRNA, 

and type II Glanzmann

,

s thrombasthenia. 

J Thromb Haemost 2003;1:1071–8.

19. Mansour W., Einav Y., Hauschner H. 

et al. An 

α

IIb mutation in patients with 

Glanzmann thrombasthenia located in the 

N-terminus of blade 1 of the betapropeller 

(Asn2Asp) disrupts a calcium binding site in 

blade 6. J Thromb Haemost 2011;9:192–200.

20. Raccuglia G. Grey platelet syndrome: 

a variety of qualitative platelet disorder. Am 

J Med 1971;51:818–28.

21. Gerrard J. M., Phillips D. R., Rao G. H. 

et al. Biochemical studies of two patients with 

the grey platelet syndrome. J Clin Invest 

1980;66:102–9.

22. Levy-Toledano S., Caen J. P., 

 Breton-Gorius J. et al. Gray platelet 

syndrome: alpha-granule deficiency. Its 

influence on platelet function. J Lab Clin 

Med 1981;98:831–48.

23. Nurden A. T., Kunicki T. J., Dupuis G. 

et al. Specific protein and glycoprotein 

deficiencies in platelets isolated from two 

patients with the grey platelet syndrome. 

Blood 1982;59:709–18.

24. Maynard D. M., Heijnen H. F., Gahl W. A. 

et al. The alpha granule proteome: novel proteins 

in normal and ghost granules in gray platelet 

syndrome. J Thromb Haemost 2010;8:1786–96.

25. White J. G. Ultrastructural studies of the 

gray platelet syndrome. Am J Pathol 

1979;95:445–62.

26. Nurden A. T., Nurden P. The gray platelet 

syndrome: clinical spectrum of the disease. 

Blood Rev 2007;21:21–36.

27. Nurden A. T., Nurden P. Inherited defects 

of platelet function. Rev Clin Exp Hematol 

2001;5:314–34.

28. Gunay-Aygun M., Zivony-Elboum Y., 

Gumruket F. et al. Gray platelet syndrome: 

natural history of a large patient cohort and 

locus assignment to chromosome 3p. Blood 

2010;116:4990–5001.

29. Tubman V. N., Levine J. E., 

Campagnaet D. R. et al. X-linked gray 

platelet syndrome due to a GATA1 Arg216Gln 

mutation. Blood 2007;109:3297–9.

30. Monteferrario D., Bolar N. A., 

Marnethet A. E. et al. A dominant-negative 

GFI1B

 mutation in the gray platelet 

syndrome. N Engl J Med 2014;  

370:245–53.

31. Albers C. A., Cvejic A., Favier R. et al. 

Exome sequencing identifies NBEAL2 as the 

causative gene for gray platelet syndrome. Nat 

Genet 2011;43:735–7.

32. Andrews R. K., Berndt M. C. Bernard – 

Soulier syndrome: an update. Semin Thromb 

Hemost 2013;39:656–62.

33. Buchbinder D., Nugent D. J., 

Fillipovich A. H. Wiskott–Aldrich syndrome: 

diagnosis, current management, and 

emerging treatments. Appl Clin Genet 

2014;7:55–66.

34. Zhang S., Zhou X., Liu S. et al.  

MYH9-related disease: description  

of a large Chinese pedigree and a survey of 

reported mutations. Acta Haematol 

2014;132:193–8.

35. Nurden A. T. Qualitative disorders 

of platelets and megakaryocytes. J Thromb 

Haemost 2005;3:1773–82.

36. Zwaal R. F., Comfurius P., Bevers E. M. 

Scott syndrome, a bleeding disorder caused 

by defective scrambling of membrane 

phospholipids. Biochim Biophys Acta 

2004;1636:119–28.